MarketPulse

inflammation

5 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

AbbVie Backs Montreal Biotech RIME Therapeutics With Innovation Award

AbbVie awards RIME Therapeutics incubation support at Montreal's adMare Centre, providing laboratory space, equipment access, and mentorship for its inflammation-focused peptide platform.
ABBVimmunologydrug discovery
GlobeNewswire Inc.GlobeNewswire Inc.··Bioage Labs, Inc.

BioAge's BGE-102 Shows Best-in-Class Inflammation Reduction in Phase 1 Trial

BioAge's BGE-102 achieves best-in-class hsCRP reductions of ≥85% in Phase 1, with excellent tolerability. Phase 2 cardiovascular and diabetic macular edema trials planned for mid-2026.
BIOAPhase 1 clinical trialdiabetic macular edema
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Nurix Therapeutics Posts $87.2M Loss While Advancing Bexobrutideg Clinical Pipeline

Nurix Therapeutics reported Q1 2026 revenue of $6.3M (down 66% YoY) and $87.2M net loss, maintaining $540.7M cash while advancing bexobrutideg clinical program.
SNYGILDNRIXclinical trialsimmunology
BenzingaBenzinga··Vandana Singh

Sanofi's Dual-Action Drug Shows Promise Beyond Lungs in Asthma, Polyp Trials

Sanofi's lunsekimig met primary endpoints in asthma and nasal polyp trials but failed dermatitis goals, showing favorable safety across all studies.
SNYUPBREGNGSKatopic dermatitisPhase 2 trials
GlobeNewswire Inc.GlobeNewswire Inc.··Cadrenal Therapeutics, Inc.

Cadrenal's Novel 12-LOX Inhibitor Shows Promise in Obesity and Diabetes Research

Cadrenal's 12-LOX inhibitor CAD-1005 shows preclinical promise for obesity and diabetes inflammation reduction, potentially complementing GLP-1 medications.
CVKDclinical developmentGLP-1 medications